Beyond the pink ribbon: Is breast cancer cause marketing ready for its next revolution?

Thirty-three years after we launched the Avon Breast Cancer Crusade, it's time to ask whether corporate America is truly changing women's health—or simply turning more products pink.

Breast cancer doesn't need another pink ribbon. It needs companies willing to change the outcomes.

Every October, brands turn pink. Products proliferate, donations are announced, and awareness campaigns fill our social feeds. But after more than three decades, we should be asking a tougher question: Are companies using their power to advance women's health, or simply borrowing the power of a cause to advance their brands?

For me, this question is deeply personal.

In 1993, when my team and I created the Avon Breast Cancer Crusade in partnership with their leadership, we recognized something powerful: Avon's greatest asset wasn't its beauty products. It was its trusted relationships with millions of women, from its representatives to consumers.

At a time when breast cancer was discussed in whispers, Avon representatives could spark conversations, share vital information, and inspire action in communities around the world.

We turned that extraordinary network into a global movement that ultimately generated more than $950 million, reached 180 million people with breast health education, and funded screenings for 20 million women. But the real breakthrough wasn't the money or the scale. It was proving that a company's greatest business strengths could become its greatest contribution to society. That was the promise of cause marketing then. And it should be the standard for corporate leadership today.

Who's Still Leading—and What's Really Changing?

More than three decades after breast cancer became a signature corporate cause, several pioneers remain committed. But the real distinction is whether companies are simply funding the cause or applying their unique capabilities to change outcomes.

Avon: Mobilizing personal connections. The Breast Cancer Crusade transformed Avon's network of millions of representatives into a global force for women's health. Today's Feel the Boob Love initiative continues its education mission. The next opportunity: convert trusted relationships into measurable improvements in screening, early detection, and access to care.

Estée Lauder: Advancing scientific discovery. A pioneer of the pink ribbon, Estée Lauder has committed $15 million to research breast cancer in younger women. This represents a shift from raising awareness to addressing an emerging scientific challenge. Success will ultimately be measured by advances in prevention, detection, and treatment.

Ralph Lauren: Building healthcare infrastructure. Pink Pony has evolved beyond fundraising, with a $25 million commitment to establish or expand cancer centers. Its opportunity is to demonstrate lasting improvements in access, early diagnosis, and care for underserved communities.

Ford: Applying business expertise. Warriors in Pink has contributed more than $139 million while addressing transportation barriers and developing innovations such as the post-surgery SupportBelt. Ford demonstrates how corporate expertise can address practical patient needs. The challenge is scaling these solutions and measuring their impact.

Delta Air Lines: Mobilizing people and resources. Delta has raised $36 million for research through employee and customer engagement. Could its transportation expertise and global network also help patients overcome barriers to reaching treatment?

These commitments deserve recognition. But longevity and dollars raised are not, by themselves, measures of leadership.

The next evolution in cause marketing must move beyond what companies give to what they uniquely change, improving access, removing barriers, accelerating research, and ultimately saving lives.

A New Urgency: Younger Women and Underserved Communities

One of the most troubling developments is the rising incidence of breast cancer among younger women. According to the American Cancer Society, incidence has been increasing approximately 1% annually—and 1.4% among women under 50.

These women face distinctive challenges involving careers, young families, fertility, finances, and treatment decisions. Many are below the recommended age for routine mammograms for average-risk women. Companies are beginning to respond.

In September 2026, Sisters Network Inc. launched SIS Talks: Breast Health Unfiltered, a TikTok campaign targeting young Black women. Supported by Novartis and other pharmaceutical companies, it uses survivor stories and culturally relevant conversations to address breast health disparities.

The next generation of breast cancer programs must recognize that women are not one homogeneous audience. Younger women, Black and Hispanic women, rural women, and those facing financial barriers require more targeted solutions.

When Pink Is Only Skin Deep

Unfortunately, not every breast cancer campaign demonstrates this depth. Each October, countless products turn pink. Some raise meaningful funds. Others generate more brand visibility than tangible benefit.

In 2025, activewear company Set Active faced criticism after initially pledging just 2% of sales from its breast cancer collection to charity. Following consumer backlash, it increased its contribution to 20% of gross sales. The lesson? Consumers are scrutinizing the substance behind the ribbon.

There's nothing inherently wrong with a pink product or modest donation. But meaningful cause marketing should answer three questions:

• What's the impact? Beyond dollars raised, what meaningful change results?

• Why this company? What distinctive capabilities does it contribute?

• What's the lasting commitment? Does the work extend beyond October?

Without convincing answers, cause marketing risks becoming cause decoration.

The Leadership Challenge: Stop Wearing the Cause. Start Changing Its Future.

The breast cancer movement has achieved extraordinary progress. U.S. mortality rates have declined approximately 44% since 1989, thanks to advances in detection and treatment. But awareness alone is no longer enough.

When we created the Avon Breast Cancer Crusade, we weren't trying to put a pink ribbon on a beauty company. We were trying to put the power of a beauty company to build a movement. That's a fundamental difference that still defines the best of corporate purpose.

Today, I challenge corporate leaders to ask: What can we uniquely do that others cannot? Can our technology accelerate detection? Can our distribution networks reach women overlooked by the healthcare system? Can our employees, expertise, and partnerships eliminate barriers to treatment?

And, most importantly, can we demonstrate that lives are better because we chose to act?

Thirty-three years after launching the Avon Breast Cancer Crusade, I remain as convinced as ever that companies have extraordinary power to change society. But that power is only meaningful when they move beyond association with a cause to ownership of a solution.

The next revolution in breast cancer cause marketing won't be measured by how much pink we see. It will be measured by how many lives we change.